Plan Overview

_A Data Management Plan created using DMPTool_

**DMP ID:** [https://doi.org/10.48321/D1362Q](https://doi.org/10.48321/D1362Q)

**Title:** Gene Expression and Biomarker Utility in Postmortem Samples

**Creator:** Scott Nicholson - **ORCID:** [0000-0002-2201-744X](https://orcid.org/0000-0002-2201-744X)

**Affiliation:** Civil Aerospace Medical Institute (faa.gov)

**Principal Investigator:** Scott Nicholson

**Data Manager:** Scott Nicholson

**Project Administrator:** Scott Nicholson

**Funder:** Federal Aviation Administration (faa.gov)

**Funding opportunity number:** na

**Grant:** na

**Template:** Federal Aviation Administration (FAA) Data Management Plan (DMP) Template v1.1

**Project abstract:**

This study is intended to identify genetic biomarkers associated with consumption of cannabis in order to expand thresholds of detection and ability to detect use of drugs that are difficult to assay with traditional biochemistry-based toxicology assays. This project will produce a method of genetics-based detection of drug use in sample specimens used for traditional biochemical-based toxicology, thereby expanding the ability to detect use of drugs in toxicology samples. This project will expand the FAA's ability to assay toxicology samples and will produce biomarkers of THC use for use in future work.
Start date: 09-30-2019

End date: 09-26-2024

Last modified: 05-12-2023

Copyright information:

The above plan creator(s) have agreed that others may use as much of the text of this plan as they would like in their own plans, and customize it as necessary. You do not need to credit the creator(s) as the source of the language used, but using any of the plan's text does not imply that the creator(s) endorse, or have any relationship to, your project or proposal.
Gene Expression and Biomarker Utility in Postmortem Samples

Persistent Link

Include the persistent identifier (PID) that is associated with the dataset.

Persistent Link: tbd

Recommended Citation

The recommended data citation to be used when citing the dataset.

Recommended Citation: tbd

Change Log

Document the changes that are made to the DMP, any and all changes should be noted to ensure a more complete documentation.

Change Log: NEW DMP 2023_01_13

Table of Contents

Optional table of contents included here, in order to better organize the DMP.

NA

0. Dataset and Contact Information

Please provide the following information:

- Name of the dataset or project for which data is being collected.
- Name of the FAA Line-Of-Business/Office for which the associated dataset is being generated.
- Email for the FAA Line-Of-Business/Office (key field).
- If applicable and as reference, project number, contract number, or other number used to link this DMP.
0. Dataset and Contact Information:
   Project: Gene Expression and Biomarker Utility in Postmortem Samples

   FAA line-of-business: AAM-600, Aerospace Medical Research Division

   Email: scott.nicholson@FAA.GOV

   Project number: a11j.am.11

1. Data Description

Name the data, data collection project, or data producing program. Provide high level narrative.

RNAseq data in the form of fastq files will be produced during this research.

Other data, including aviation accident data, drug detection data, and other data will be in the form of .txt, .xlsx, .csv, or other standard formats.

All data will be de-identified.

Describe the purpose of your research and whether results will be documented in a published document or report. How will it be used?

The purpose of this research is to 1) determine how useful aviation accident autopsy samples are in detecting gene expression, and 2) what RNA biomarker of cannabis use can be found in such samples. The data and study findings will be published in a publicly available format, to be determined at a later date.

Describe the data that will be generated in terms of nature and scale (e.g., numerical data, image data, text sequences, video, audio, database, modeling data, source code, etc.).

All data produced during this study will be in a text format, as described above.

Describe methods for creating the data (e.g., simulated; observed; experimental; software; physical collections; sensors; satellite; enforcement activities; researcher-generated databases, tables, and/or spreadsheets; instrument generated digital data output such as images and video;
Data will be collected from observations (autopsy data), toxicological analyses, and RNA sequencing.

**Describe the period of time over which the data will be collected and frequency at which it will be updated.**

Samples were collected from 10/1/2019 until 07/01/2022.

Data from these samples was collected during this period.

RNAseq data will be collected throughout 2023.

**If using existing data, describe the relationship between the data you are collecting and existing data.**

Existing autopsy, toxicological, and investigatory data will be collected from the FAA ToxDB system.

**Describe potential users of the data and the expected manner in which they may use it.**

The data may be used in scientific research, such as medical or addiction research, and also by policymakers, industry researchers, or other unanticipated users.

**Discuss the potential value of having the data available not only to your institution but also for the public, e.g., might be renewed interest and value in reanalyzing the data with updated and more universally comparable metrics or recently developed analytical methods.**

This data may be useful for medical and addiction research.

**State clearly if data can be shared publicly or not. If you request permission not to make data publicly accessible, explain rationale for lack of public access.**

Data from this study will be shared through a limited-access government database, and made available for legitimate research purposes.

Other data will be shared publicly through a technical report.

**Indicate the party responsible for managing the data.**

FAA AAM-600

**Describe how you will check for adherence to this data management plan.**

NA

---

Created using DMPTool. Last modified 12 May 2023
2. Standards Employed

List in what format(s) the data will be collected. Indicate if they are open or proprietary.

Sequence data will be in .fastq format

Other data will be in standard .txt, .doc, .docx, or .xlsx format.

All are open formats

If you are using proprietary data formats, discuss your rationale for using those standards and formats.

na

Describe how versions of data be signified and/or controlled.

Original data will be stored without modification.

Interim data versioning will be reflected by file naming including dates, version numbers, or iteration numbers.

Final data will be marked 'final'.

If the file format(s) you are using is(are) not standard to your field, describe how you will document the alternative you are using.

NA

List what documentation you will be creating in order to make the data understandable by other researchers.

The data generated here will be described in technical reports and using metadata standards consistent with NCBI repository requirements.

Indicate what metadata schema you are using to describe the data. If the metadata schema is not one standard for your field, discuss your rationale for using that scheme.

Standard NCBI metadata schema will be employed.
Describe how will the metadata be managed and stored.

NA

Indicate what tools or software is required to read or view the data.

Standard text editors may be employed to read the raw data.

The raw data is not amenable to direct viewing, summaries of the data and its significance will be made available in technical report(s).

Describe your quality control measures.

There are a number of open-source quality control software packages, such as multiQC and fastQC, that will be used to assess data quality.

3. Access Policies

Describe what data will be publicly shared, how data files will be shared, and how others will access them.

Technical reports including non-identifying raw and summarized data will be made available through Office of Aerospace Medicine reports and other publicly-accessible technical publications.

Raw sequence data will be made available to researchers through restricted-access NIH repositories designed to house that data.

Indicate whether the data contain private or confidential information. If so:

- Discuss how will you guard against disclosure of identities and/or confidential business information.
- List what processes you will follow to provide informed consent to participants.
- State the party responsible for protecting the data.

All data involved in this study was de-identified at the site of collection.

RNA sequence data will be treated as sensitive data, and will be released in the restricted-access dbGaP NIH repository as described previously.
If applicable, describe how you will deidentify your data before sharing. If not:

- Identify what restrictions on access and use you will place on the data.
- Discuss additional steps, if any you will use to protect privacy and confidentiality.

Non-sequence data will not be restricted.

Sequence data will be available to researchers who apply for access through the dbGaP data use committee.

4. Re-Use, Redistribution, and Derivative Products Policies

Name who has the right to manage the data.

Unless otherwise noted, the data described in this DMP is generated and managed by the Federal Aviation Administration. The data are in the public domain, and may be re-used without restriction.

Indicate who holds the intellectual property rights to the data.

Unless otherwise noted (e.g., data is partially proprietary by an external entity, where intellectual property is shared), this data is required to be made available in open, machine-readable formats, while continuing to ensure privacy and security in accordance with the OPEN Government Data Act, which is Title II of the Foundations for Evidence-Based Policymaking Act.

List any copyrights to the data. If so, indicate who owns them.

NA

Discuss any rights that are transferred to a data archive.

NA

Describe how your data will be licensed for reuse, redistribution, and derivative products.

Unless otherwise noted, there is not a need for the data in this DMP to be licensed for reuse, redistribution, and/or its derivative products.

5. Archiving and Preservation Plans
Discuss how you intend to archive your data and where (include URL).

Unless otherwise noted, the data described in this DMP will be uploaded to the FAA's Enterprise Information Management (EIM) through the FAA Data Governance Center. This is the internal FAA landing page and access point to EIM uploaded datasets and processes. Here the metadata is curated and validated for quality and accuracy. The FAA Data Steward enters metadata and verifies quality and accuracy before publishing to data.faa.gov, which is the FAA's clearinghouse site for publicly available FAA data and managed and hosted by the FAA’s, IT Shared Services organization - Chief Data Office, see https://catalog.data.faa.gov/about for more information.

Technical reports and non-sequence data generated in this project will be placed in the National Transportation library

Sequence data generated during this project will be placed in the NIH dbGaP repository.

Indicate the approximate time period between data collection and submission to the archive.

Data and all research products (e.g., reports) are expected to be submitted within the period-of-performance of the research, which is planned to conclude 09/30/2024

Identify where data will be stored prior to being sent to an archive.

Data will be stored in a secure cloud environment and on secure drives within CAMI.

Describe how back-up, disaster recovery, off-site data storage, and other redundant storage strategies will be used to ensure the data's security and integrity, initially and for the long-term.

Off-site data storage will be provided within a secure cloud environment.

Small data files will be stored in duplicate on separate secure drives.

Describe how data will be protected from accidental or malicious modification or deletion prior to receipt by the archive.

Data will be stored in controlled-access sites, access will not be granted to individuals not involved in the research.

Original data will be stored in multiple secure locations.

Indicate how long the chosen archive will retain the data.

Unless otherwise noted, the long term storage of the data described in this DMP will persist indefinitely in the FAA's Enterprise Information Management (EIM) platform following standard government policies and best practices.
Raw sequence data will be stored on the NIH dbGaP repository.

**Indicate if the chosen archive employs, or allows for the recording of, persistent identifiers linked to the data.**

dbGaP employs persistent identifiers.

**Discuss how your chosen data repository meets the criteria outlined on the [Guidelines for Evaluating Repositories for Conformance with the DOT Public Access Plan](https://doi.org/10.21949/1503647) page.**

NIH dbGaP is a government-maintained repository that meets all federal requirements and serves as the repository of record for human sequence data.

### 6. Policies Affecting this Data Management Plan

Include policies that the data management plan was created to meet, such as the DOT public access plan.

This data management plan was created to meet the requirements enumerated in the U.S. Department of Transportation's "Plan to Increase Public Access to the Results of Federally-Funded Scientific Research" Version 1.1 [https://doi.org/10.21949/1520559](https://doi.org/10.21949/1520559) and guidelines suggested by the DOT Public Access website [https://doi.org/10.21949/1503647](https://doi.org/10.21949/1503647), in effect and current as of 2023_01_13.
Planned Research Outputs

Data paper - "Gene Expression and Biomarker Utility in Postmortem Samples"

NONE AT PRESENT

---

Planned research output details

<table>
<thead>
<tr>
<th>Title</th>
<th>Type</th>
<th>Anticipated release date</th>
<th>Initial access level</th>
<th>Intended repository(ies)</th>
<th>Anticipated file size</th>
<th>License</th>
<th>Metadata standard(s)</th>
<th>May contain sensitive data?</th>
<th>May contain PII?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene Expression and Biomarker Utility in Postmortem ...</td>
<td>Data paper</td>
<td>2024-09-29</td>
<td>Open</td>
<td>NCBI</td>
<td>1 TB</td>
<td>Creative Commons Attribution 4.0 International</td>
<td>None specified</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>